central nervous system diseases

Summary

Summary: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.

Top Publications

  1. ncbi Necrotizing neurosarcoid: three cases with varying presentations
    J M Markert
    Department of Surgery, Division of Neurosurgery, University of Alabama at Birmingham, AL 35294, USA
    Clin Neuropathol 26:59-67. 2007
  2. ncbi Central nervous system effects in acute thallium poisoning
    Yu tai Tsai
    Department of Neurology, Chang Gung Memorial Hospital and University, 199 Tung Hwa North Road, Taipei, Taiwan
    Neurotoxicology 27:291-5. 2006
  3. ncbi Childhood chronic inflammatory demyelinating polyneuropathy with central nervous system demyelination resembling multiple sclerosis
    M Victoria Rodriguez-Casero
    Department of Neurology, Royal Children s Hospital, Flemington Road, Parkville, VIC 3052, Australia
    Neuromuscul Disord 13:158-61. 2003
  4. ncbi Metabolomics: a global biochemical approach to the study of central nervous system diseases
    Rima Kaddurah-Daouk
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 34:173-86. 2009
  5. ncbi Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases
    Xue Feng Jin
    Beijing Institute of Pharmacology and Toxicology, Beijing, China
    Cell Mol Neurobiol 33:601-13. 2013
  6. ncbi Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study
    Mong How Ooi
    Department of Paediatrics, Sibu Hospital, Sibu, Malaysia
    Clin Infect Dis 44:646-56. 2007
  7. ncbi The chronic cerebrospinal venous insufficiency syndrome
    P Zamboni
    Vascular Disease Centre, Interventional Radiology Unit, University of Ferrara, 44100 Ferrara, Italy
    Phlebology 25:269-79. 2010
  8. ncbi Neural cell cycle dysregulation and central nervous system diseases
    Wei Wang
    Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    Prog Neurobiol 89:1-17. 2009
  9. pmc Antioxidants in central nervous system diseases: preclinical promise and translational challenges
    Chandrashekhar D Kamat
    Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    J Alzheimers Dis 15:473-93. 2008
  10. ncbi Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?
    T Ludyga
    EUROMEDIC Specialist Clinics, Department of Vascular and Endovascular Surgery, Katowice, Poland
    Phlebology 25:286-95. 2010

Detail Information

Publications243 found, 100 shown here

  1. ncbi Necrotizing neurosarcoid: three cases with varying presentations
    J M Markert
    Department of Surgery, Division of Neurosurgery, University of Alabama at Birmingham, AL 35294, USA
    Clin Neuropathol 26:59-67. 2007
    ..This paper documents three additional cases of necrotizing neurosarcoid, involving a wide spectrum of central nervous system (CNS) locations...
  2. ncbi Central nervous system effects in acute thallium poisoning
    Yu tai Tsai
    Department of Neurology, Chang Gung Memorial Hospital and University, 199 Tung Hwa North Road, Taipei, Taiwan
    Neurotoxicology 27:291-5. 2006
    ..In addition, neuropsychological tests also confirmed memory deficits, although the brain lesions in the corpus striatum might resolve...
  3. ncbi Childhood chronic inflammatory demyelinating polyneuropathy with central nervous system demyelination resembling multiple sclerosis
    M Victoria Rodriguez-Casero
    Department of Neurology, Royal Children s Hospital, Flemington Road, Parkville, VIC 3052, Australia
    Neuromuscul Disord 13:158-61. 2003
    ..To our knowledge, this association has not been previously described in the English literature in childhood...
  4. ncbi Metabolomics: a global biochemical approach to the study of central nervous system diseases
    Rima Kaddurah-Daouk
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 34:173-86. 2009
    ..Metabolomics emerges as another powerful tool in central nervous system research...
  5. ncbi Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases
    Xue Feng Jin
    Beijing Institute of Pharmacology and Toxicology, Beijing, China
    Cell Mol Neurobiol 33:601-13. 2013
    ....
  6. ncbi Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study
    Mong How Ooi
    Department of Paediatrics, Sibu Hospital, Sibu, Malaysia
    Clin Infect Dis 44:646-56. 2007
    ..Human enterovirus (HEV)-71 causes large outbreaks of hand-foot-and-mouth disease with central nervous system (CNS) complications, but the role of HEV-71 genogroups or dual infection with other viruses in causing severe disease is unclear...
  7. ncbi The chronic cerebrospinal venous insufficiency syndrome
    P Zamboni
    Vascular Disease Centre, Interventional Radiology Unit, University of Ferrara, 44100 Ferrara, Italy
    Phlebology 25:269-79. 2010
    ..Restenosis rate was found out elevated in the IJVs, but negligible in the AZ. However, PTA seems to positively influence clinical and QoL parameters of the associated MS and warrants further randomized control trials...
  8. ncbi Neural cell cycle dysregulation and central nervous system diseases
    Wei Wang
    Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    Prog Neurobiol 89:1-17. 2009
    ..This review summarizes advances in findings implicating cell cycle machinery in neuronal death in CNS diseases...
  9. pmc Antioxidants in central nervous system diseases: preclinical promise and translational challenges
    Chandrashekhar D Kamat
    Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    J Alzheimers Dis 15:473-93. 2008
    ....
  10. ncbi Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?
    T Ludyga
    EUROMEDIC Specialist Clinics, Department of Vascular and Endovascular Surgery, Katowice, Poland
    Phlebology 25:286-95. 2010
    ..Although balloon angioplasty and stenting seem to be safe procedures, there are currently no data on the treatment of a large group of patients with this vascular pathology...
  11. ncbi Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations
    R G Thorne
    Department of Pharmaceutics, University of Minnesota, Minneapolis, Minnesota, USA
    Clin Pharmacokinet 40:907-46. 2001
    ....
  12. ncbi Detection of myelin autoantibodies: evaluation of an assay system for diagnosis of multiple sclerosis in differentiation from other central nervous system diseases
    Markus Langkamp
    Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH, Reutlingen, Germany
    Clin Chem Lab Med 47:1395-400. 2009
    ..This tool could help define autoimmune status and thus be a potential means of therapeutic surveillance...
  13. ncbi Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions
    Barbara Rossi
    Department of Pathology and Diagnostics, Section of General Pathology, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy
    J Leukoc Biol 89:539-56. 2011
    ..These emerging roles for leukocytes and leukocyte adhesion mechanisms in CNS diseases provide insight into the mechanisms of brain damage and may contribute to the development of novel therapeutic strategies...
  14. ncbi Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases
    Anita Greco
    Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Rome, Italy
    Curr Neurovasc Res 1:341-54. 2004
    ..biomarkers to investigate the involvement of oxidative stress in the pathogenesis of infant and adult central nervous system diseases. In addition to isoprostanes, a new class of free radical-mediated peroxidation products, named ..
  15. ncbi Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab
    Gunnar Sturfelt
    J Rheumatol 34:2313-4. 2007
  16. ncbi Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond
    Andrew McKeon
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 68:1282-9. 2011
    ..To investigate the full extent of Purkinje cell cytoplasmic autoantibody type 1 autoimmunity (classically associated with paraneoplastic cerebellar degeneration) from clinical, immunohistochemical, and neuropathological perspectives...
  17. pmc Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6
    I L Campbell
    Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037
    Proc Natl Acad Sci U S A 90:10061-5. 1993
    ..These findings indicate that cytokines such as IL-6 can have a direct pathogenic role in inflammatory, infectious, and neurodegenerative CNS diseases...
  18. ncbi The role of imaging in proof of concept for CNS drug discovery and development
    Dean F Wong
    Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine, 601 North Caroline St, JHOC room 3245, Baltimore, MD 21287 0807, USA
    Neuropsychopharmacology 34:187-203. 2009
    ..In summary, this article reviews the vital biomarker approach of neuroimaging in proof of concept studies...
  19. ncbi Inner ear lesions in congenital cytomegalovirus infection of human fetuses
    Natacha Teissier
    Pediatric ENT Department, Robert Debre Hospital, APHP, Paris, France
    Acta Neuropathol 122:763-74. 2011
    ..In addition, the occurrence of SNHL depends on the intensity and duration of the viral infection and inflammation...
  20. pmc Altered development of the brain after focal herpesvirus infection of the central nervous system
    Thad Koontz
    Department of Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 205:423-35. 2008
    ..These findings suggested that in the developing CNS, focal virus infection and induction of inflammatory responses in resident and infiltrating mononuclear cells resulted in delayed cerebellar morphogenesis...
  21. ncbi Purinergic signalling and disorders of the central nervous system
    Geoffrey Burnstock
    Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    Nat Rev Drug Discov 7:575-90. 2008
    ....
  22. pmc Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease
    Shuzhen Guo
    Neuroprotection Research Laboratory, MGH East 149 2401, 13th Street, Charlestown, MA 02129, USA
    Stroke 40:S4-7. 2009
    ..This minireview surveys recent data that support this basic idea, with examples drawn from experimental models broadly relevant to stroke and neurodegeneration...
  23. ncbi Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000)
    L F Eng
    Department of Pathology, VAPA Health Care System, Palo Alto 94304, USA
    Neurochem Res 25:1439-51. 2000
    ..While the structural function of GFAP has become more acceptable, the use of GFAP antibodies and promoters continue to be valuable in studying CNS injury, disease, and development...
  24. ncbi Inflammation in the CNS: balance between immunological privilege and immune responses
    M K Matyszak
    CNR, Centre of Cellular and Molecular Pharmacology, Milano, Italy
    Prog Neurobiol 56:19-35. 1998
    ..Pathogens injected into the ventricles induce inflammatory responses similar to those in other non-CNS tissues: there is an acute inflammatory response which develops spontaneously into an immune mediated response within the first week...
  25. ncbi Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders
    Jacques de Keyser
    Department of Neurology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
    J Neurol Sci 267:3-16. 2008
    ..Targeting astrocyte dysfunction may lead to new therapeutic strategies for these disorders...
  26. pmc Molecular pathogenesis of neuroinflammation
    M Bradl
    Institute for Brain Research, Department of Neuroimmunology, Vienna, Austria
    J Neurol Neurosurg Psychiatry 74:1364-70. 2003
    ..The review is limited to the inflammatory reactions of the central nervous system that occur in multiple sclerosis and experimental autoimmune encephalomyelitis...
  27. ncbi Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?
    Gerd Schmitz
    Institute for Clinical Chemistry and Laboratory Medicine, University Hospital of Regensburg, Germany
    Cent Nerv Syst Agents Med Chem 9:307-30. 2009
    ..They are suitable biomarker targets for diagnosis and prognosis and maybe also therapy of central nervous system disease...
  28. ncbi Changing incidence of central nervous system diseases in the EuroSIDA cohort
    Antonella d'Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, I Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Ann Neurol 55:320-8. 2004
    ....
  29. ncbi Abnormal hyperintensity within the subarachnoid space evaluated by fluid-attenuated inversion-recovery MR imaging: a spectrum of central nervous system diseases
    Masayuki Maeda
    Department of Radiology, Mie University School of Medicine, 2 174 Edobashi, Tsu, 514 8507 Mie, Japan
    Eur Radiol 13:L192-201. 2003
    ..This knowledge is helpful in establishing the correct diagnosis...
  30. pmc Potential involvement of the extracranial venous system in central nervous system disorders and aging
    Robert Zivadinov
    Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA
    BMC Med 11:260. 2013
    ..The idea has been changing with regards to the extracranial venous system...
  31. pmc CD8+ T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals
    Glenn R B Bantug
    Department of Microbiology, University of Alabama at Birmingham, Alabama 35294, USA
    J Immunol 181:2111-23. 2008
    ..In summary, these results show that functionally mature virus-specific CD8(+) T cells are recruited to the CNS in mice infected with MCMV as neonates...
  32. pmc Venous endothelial injury in central nervous system diseases
    Jonathan S Alexander
    Department of Molecular and Cellular Physiology, LSU Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130 3932, USA
    BMC Med 11:219. 2013
    ....
  33. ncbi Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease
    M Brenner
    Department of Neurobiology, University of Alabama Birmingham, Birmingham, Alabama, USA
    Nat Genet 27:117-20. 2001
    ..Alexander disease therefore represents the first example of a primary genetic disorder of astrocytes, one of the major cell types in the vertebrate CNS...
  34. ncbi Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases
    Marie C Mayer
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, 81377 Munich, Germany
    J Immunol 191:3594-604. 2013
    ..The majority of human anti-MOG Abs did not recognize rodent MOG, which has implications for animal studies. Our findings might assist in future detection of potential mimotopes and pave the way to Ag-specific depletion. ..
  35. ncbi Isorhynchophylline: A plant alkaloid with therapeutic potential for cardiovascular and central nervous system diseases
    Ji Yin Zhou
    Base for Drug Clinical Trial, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
    Fitoterapia 83:617-26. 2012
    ..It requires more in vivo validations and further investigations of antihypertensive and neuroprotective mechanisms of isorhynchophylline...
  36. ncbi The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidence
    Samuel D Banister
    Brain and Mind Research Institute, 100 Mallett St, Camperdown, NSW 2050, Australia
    Curr Pharm Des 18:884-901. 2012
    ..This review will assess the validity of receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials...
  37. ncbi Therapeutic potential of small interfering RNA for central nervous system diseases
    Amy E Lovett-Racke
    Department of Neurology, UT Southwestern Medical Center, Dallas, Tex 75390 9036, USA
    Arch Neurol 62:1810-3. 2005
  38. ncbi Brain-derived neurotrophic factor as a drug target for CNS disorders
    Sophie Pezet
    Novartis Institute for Medical Science, London, UK
    Expert Opin Ther Targets 8:391-9. 2004
    ..The cellular and molecular mechanism by which BDNF might be a therapeutic strategy are critically examined...
  39. ncbi Neuro-immune crosstalk in CNS diseases
    M Kerschensteiner
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University Munich, Marchioninistr 17, 81377 Munich, Germany
    Neuroscience 158:1122-32. 2009
    ..It is thus the balance between destructive and protective factors that ultimately determines the net result of the neuro-immune interaction...
  40. pmc Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells
    Derek D C Ireland
    The Cleveland Clinic, 2500 Euclid Avenue, NC30, Cleveland, OH 44195, USA
    J Virol 82:300-10. 2008
    ..By limiting early viral replication and tropism, IFN-I controls the balance of viral replication and immune control in favor of CD8 T-cell-mediated protective functions...
  41. pmc Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology
    Meizhang Li
    Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Mail Code NC30, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Prog Neurobiol 84:116-31. 2008
    ....
  42. ncbi Astrocyte intermediate filaments in CNS pathologies and regeneration
    Milos Pekny
    Department of Medical Biochemistry, Sahlgrenska Academy at Goteborg University, Box 430, 405 30 Goteborg, Sweden
    J Pathol 204:428-37. 2004
    ..GFAP is the principal astrocyte intermediate filament protein and dominant mutations in the GFAP gene have been shown to lead to Alexander disease, a fatal neurodegenerative condition in humans...
  43. ncbi Influence of HAART on HIV-related CNS disease and neuroinflammation
    I C Anthony
    Neuropathology Unit, University of Edinburgh, Alexander Donald Building, Western General Hospital, Edinburgh, Scotland
    J Neuropathol Exp Neurol 64:529-36. 2005
    ..We conclude that there is a surprising degree of ongoing neuroinflammation in HAART-treated patients, particularly in the hippocampus. This may pose a threat for the future health of individuals maintained long-term on HAART therapy...
  44. ncbi Microglial cell population dynamics in the injured adult central nervous system
    Rune Ladeby
    Medical Biotechnology Center, University of Southern Denmark, Odense C
    Brain Res Brain Res Rev 48:196-206. 2005
    ....
  45. pmc Risks for central nervous system diseases among mobile phone subscribers: a Danish retrospective cohort study
    Joachim Schüz
    Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
    PLoS ONE 4:e4389. 2009
    ..Identification of the factors that result in a healthy cohort might be of interest for elucidation of the etiology of these diseases...
  46. ncbi Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America
    M S Saag
    University of Alabama at Birmingham, 35294 2050, USA For the Mycoses Study Group Cryptococcal Subproject
    Clin Infect Dis 30:710-8. 2000
    ..In all cases of cryptococcal meningitis, careful attention to the management of intracranial pressure is imperative to assure optimal c..
  47. ncbi Extracellular matrix degradation by metalloproteinases and central nervous system diseases
    A Lukes
    Department of Neurology, University of New Mexico School of Medicine, Albuquerque, USA
    Mol Neurobiol 19:267-84. 1999
    ..Agents that affect the proteolytic process at any of the regulating sites are potentially useful in therapy...
  48. ncbi Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death
    Steven H Graham
    Geriatric Research Educational and Clinical Center, Veterans Affairs Pittsburgh Health Care System, and the Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA
    Arch Neurol 60:628-30. 2003
  49. ncbi Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine
    Girish Dhall
    Children s Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 50:72-9. 2008
    ..To assess the activity and tolerability of 2-chlorodeoxyadenosine (2-CDA) in treating mass lesions of the central nervous system (CNS) due to Langerhans cell histiocytosis (LCH)...
  50. ncbi Mechanisms of immunopathology in murine models of central nervous system demyelinating disease
    Anne M Ercolini
    Department of Microbiology Immunology and Interdepartmental Immunobiology Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Immunol 176:3293-8. 2006
    ..This review will discuss the immunopathologic mechanisms involved in these demyelinating disease models...
  51. ncbi Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats
    F Gardoni
    Center of Excellence on Neurodegenerative Diseases and Department of Pharmacological Sciences, University of Milano, Milan, Italy
    J Neurochem 80:438-47. 2002
    ..These findings strengthen the hypothesis that altered post-synaptic glutamatergic transmission is related to deficits in learning and plasticity in this animal model...
  52. ncbi Drug Insight: steroids in CNS infectious diseases--new indications for an old therapy
    Michael T Fitch
    Department of Neurology, Center of Infection and Immunity Amsterdam, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands
    Nat Clin Pract Neurol 4:97-104. 2008
    ....
  53. ncbi The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases
    Imtiaz M Shah
    Neurological Section, SMDN Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, I 67039 Sulmona AQ, Italy
    Cardiovasc Hematol Disord Drug Targets 7:250-73. 2007
    ....
  54. pmc 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases
    Joshua Z Willey
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Arch Neurol 67:1062-7. 2010
    ....
  55. ncbi Glycogen synthase kinase 3: a drug target for CNS therapies
    Ratan V Bhat
    AstraZeneca R and D, Sodertalje, B213 231B, Sweden 151 85
    J Neurochem 89:1313-7. 2004
    ..In the present review, we summarize the properties of GSK3, and discuss the potential for such a therapy in AD, and other CNS disorders...
  56. ncbi Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases
    István Tarnawa
    Department of Electrophysiology, Pharmacology and Drug Safety Research, Budapest, 10, POB 27, Hungary
    Recent Pat CNS Drug Discov 2:57-78. 2007
    ..Such agents may offer a breakthrough in the treatment of a variety of central nervous system diseases. This review focuses on the current trends in sodium channel research, surveying the traditional and ..
  57. ncbi Transplantation of bone marrow stromal cells for treatment of central nervous system diseases
    Michael Chopp
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan, USA
    Adv Exp Med Biol 585:49-64. 2006
  58. ncbi Cerebrospinal fluid Diacron-Reactive Oxygen Metabolite levels in pediatric patients with central nervous system diseases
    Gaku Yamanaka
    Department of Pediatrics, Tokyo Medical University, Shinjuku, Tokyo, Japan
    Pediatr Neurol 39:80-4. 2008
    This study assessed the validity of cerebrospinal fluid oxidative status of pediatric patients with central nervous system diseases, using the Diacron-Reactive Oxygen Metabolites test (d-Roms; Diacron International s.r.l...
  59. ncbi [Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients]
    Hongyun Huang
    Beijing Hongtianji Neuroscience Academy, Beijing, 100144, P R China
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 23:14-20. 2009
    To analyze the therapeutic effect of olfactory ensheathing cells (OECs) transplantation for central nervous system diseases.
  60. ncbi Central nervous system-related symptoms and findings are common in acute Puumala hantavirus infection
    Timo Hautala
    Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
    Ann Med 42:344-51. 2010
    ..Recent case reports and retrospective studies suggest that NE may damage the pituitary gland. Based on these observations, our goal was to explore the nature of this complication prospectively...
  61. ncbi Molecular mechanisms of axonal damage in inflammatory central nervous system diseases
    Harald Neumann
    Neuroimmunology Unit, European Neuroscience Institute Göttingen, Gottingen, Germany
    Curr Opin Neurol 16:267-73. 2003
    ..Axonal injury has attracted considerable interest during the past few years because the degree of axonal damage appears to determine long-term clinical outcome...
  62. ncbi Microglia as mediators of inflammatory and degenerative diseases
    F Gonzalez-Scarano
    Department of Neurology, University of Pennsylvania Medical Center, Philadelphia 19104 6146, USA
    Annu Rev Neurosci 22:219-40. 1999
    ..In this review we discuss the role of microglia in three diseases in which their activity is at least partially deleterious: HIV, multiple sclerosis, and Alzheimer's disease...
  63. ncbi Inflammation in the central nervous system: the role for dendritic cells
    Mikhail Pashenkov
    Neuroimmunology Unit, Division of Neurology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Brain Pathol 13:23-33. 2003
    ..CNS DCs can therefore be viewed as a future therapeutic target in chronic inflammatory diseases such as multiple sclerosis...
  64. ncbi Analysis of cerebrospinal fluid cells by flow cytometry and immunocytochemistry in inflammatory central nervous system diseases: comparison of low- and high-density cell surface antigen expression
    A Windhagen
    Laboratory of Neuroimmunology, Department of Neurology, Medical School Hannover, Hannover, Germany
    Diagn Cytopathol 21:313-8. 1999
    ..We conclude that for examination of low-density surface markers on CSF cells, particularly with low cell counts, immunocytochemistry may be more reliable...
  65. ncbi The application of platelet-rich plasma may be a novel treatment for central nervous system diseases
    Yi Xin Shen
    Department of Orthopaedics, the Second Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province 215004, PR China
    Med Hypotheses 73:1038-40. 2009
    ....
  66. ncbi The complement system in central nervous system diseases
    H Rus
    Department of Pathology, University of Maryland, School of Medicine, Baltimore 21201, USA
    Immunol Res 24:79-86. 2001
    ..These findings indicate that complement activation and membrane assembly of C5b-9 play an important role in pathogenesis of central nervous system (CNS) disorders...
  67. ncbi Electromagnetic fields and health effects--epidemiologic studies of cancer, diseases of the central nervous system and arrhythmia-related heart disease
    Christoffer Johansen
    Department of Psychosocial Cancer Research, Institute of Cancer Epidemiology, The Danish Cancer Society, Copenhagen, Denmark
    Scand J Work Environ Health 30:1-30. 2004
    ..At present, there is little, if any, evidence that the use of mobile phones is associated with cancer in adults, including brain tumors, acoustic neuroma, cancer of the salivary glands, leukemia, or malignant melanoma of the eye...
  68. pmc Comparison of Roche MONITOR and Organon Teknika NucliSens assays to quantify human immunodeficiency virus type 1 RNA in cerebrospinal fluid
    P Spearman
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Clin Microbiol 39:1612-4. 2001
    ..Results of 282 assays were highly correlated (r = 0.826), with MONITOR values being 0.29 +/- 0.4 log(10) copies/ml (mean +/- standard deviation) values. Both assays can reliably quantify HIV-1 RNA in CSF...
  69. ncbi Human herpes virus type 7 DNA in the cerebrospinal fluid of children with central nervous system diseases
    A Pohl-Koppe
    Children s Hospital, Ludwig Maximilians University Munich, Germany
    Eur J Pediatr 160:351-8. 2001
    ..These children were diagnosed with aseptic meningitis (n = 1), viral encephalitis/meningoencephalitis (n = 2), facial palsy (n = 1), vestibular neuritis (n = 1) and febrile seizure (n = 1)...
  70. ncbi Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality
    K Goodkin
    Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, 1400 NW 10th Ave, 803 A, Miami, FL 33136, USA
    J Clin Epidemiol 54:S35-43. 2001
    ..Age associations with incidence of these disorders and with treatment foci are specified. Implications for future changes in management are discussed...
  71. ncbi Borna disease virus
    I Jordan
    Emerging Diseases Laboratory, Department of Neurology, University of California-- Irvine, Irvine, California 92697-4292, USA
    Rev Med Virol 11:37-57. 2001
    ..Experimental Borna disease in neonatal and adult rats provides an intriguing model for immune-mediated disturbances of brain development and function...
  72. ncbi Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain
    Yvan Gasche
    Department of Fundamental Neuroscience, Geneva University Hospital, Geneva Medical School, 1211 Geneva, Switzerland
    Front Biosci 11:1289-301. 2006
    ..Yet MMPs may have a detrimental or beneficial role depending on the stage of brain injury. Simple therapeutic strategies based on MMP inhibition have thus little chance to favorably alter prognosis...
  73. ncbi Nonmuscular involvement in merosin-negative congenital muscular dystrophy
    H Jacobus Gilhuis
    Department of Paediatric Neurology, Neuromuscular Centre, University Medical Centre St Radboud, 6500 HB Nijmegen, The Netherlands
    Pediatr Neurol 26:30-6. 2002
    ..The pattern of myelination of the brain and nerve conduction slowing suggests a myelination arrest. Merosin deficiency can give rise to a congestive cardiomyopathy, which is of no clinical relevance in the majority of children...
  74. ncbi Neural stem cells in the adult nervous system
    Daniele Bottai
    Stem Cell Research Institute, DIBIT, Fondazione Centro San Raffaele del Monte Tabor, 20132 Milan, Italy
    J Hematother Stem Cell Res 12:655-70. 2003
    ....
  75. ncbi Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis
    Annacarin Horne
    Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 140:327-35. 2008
    ..Prompt treatment of HLH at onset or relapse may reduce these complications...
  76. ncbi [Nervous system involvement in children suffering from disorders associated with vasculitis]
    Marek Kacinski
    Klinika Neurologii Dzieciecej, Wydział Lekarski Collegium Medicum, Uniwersytet Jagiellonski, ul Wielicka 265, 30 663 Krakow
    Neurol Neurochir Pol 38:S9-15. 2004
    ..The most frequent form of these disorders was ischaemic stroke. Authors discussed issues specific for developmental diagnostic, etiopathogenetic and therapeutic topics...
  77. ncbi Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral
    Mario J Carmosino
    University of Colorado Multiple Sclerosis Center, University of Colorado School of Medicine, Denver, 80262, USA
    Arch Neurol 62:585-90. 2005
    ..To evaluate diagnostic outcomes, especially as they relate to reason for referral, of patients referred to a university-based multiple sclerosis (MS) center for possible MS...
  78. ncbi Multiple sclerosis mimics
    Robert M Herndon
    Department of Neurology, University of Mississippi Medical School, Jackson, USA
    Adv Neurol 98:161-6. 2006
    ..In addition to the cost of treatment, many of the current treatments such as Mitoxantrone (Novantrone) are not benign and we should not subject our patients to unnecessary harmful therapies...
  79. ncbi Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV
    Laura M Sanftner
    Avigen, Inc, Alameda, CA 94502, USA
    Mol Ther 9:403-9. 2004
    ..These results have important implications for gene therapy for CNS disorders...
  80. ncbi Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway
    Lina Du
    Department of Critical Care Medicine, Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA
    J Biol Chem 279:38563-70. 2004
    ....
  81. ncbi Neurological deficit and disturbances in higher nervous activity during modeling of perinatal hypoxic-ischemic damage to the central nervous system in rat pups
    S V Lebedev
    V P Serbskii State Research Center for Social and Forensic Psychiatry, Moscow
    Bull Exp Biol Med 136:242-5. 2003
    ..The size of the ipsilateral hemisphere remained low in adult animals...
  82. ncbi Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system
    Eduardo E Benarroch
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1326-38. 2005
    ..Disturbances of these neuron-astrocyte interactions are likely to play an important role in neurologic disorders including cerebral ischemia, neurodegeneration, migraine, cerebral edema, and hepatic encephalopathy...
  83. ncbi Neurogenesis in the adult central nervous system
    Philippe Taupin
    National Neuroscience Institute, Singapore, 11 Jalan Tan Tock Seng, Singapore 308433
    C R Biol 329:465-75. 2006
    ..Thus, not only neurogenesis contributes to reshaping the adult brain, it will ultimately lead us to redefine our knowledge and understanding of the nervous system...
  84. ncbi BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development
    Yihru Fannjiang
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Dev Cell 4:575-85. 2003
    ..BAK can alter neurotransmitter release in a direction consistent with its protective effects on neurons and mice. These findings suggest that BAK inhibits cell death by modifying neuronal excitability...
  85. ncbi Frameshift mutation in GJA12 leading to nystagmus, spastic ataxia and CNS dys-/demyelination
    Nicole I Wolf
    Clinical and Molecular Genetics Unit, Institute of Child Health, London, UK
    Neurogenetics 8:39-44. 2007
    ..In children with nystagmus, ataxia and dysmyelination, mutation analysis of GJA12 should be considered early, especially if inheritance is autosomal recessive...
  86. ncbi Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases
    Ronald Jemmerson
    Department of Microbiology and Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Antioxid Redox Signal 7:1158-72. 2005
    ..Because of their distinct mechanisms for Cyt c release, both the mPT and proapoptotic proteins should be targeted for effective clinical intervention in CNS disorders involving apoptosis...
  87. pmc Magnetic resonance imaging of neural circuits
    Jeff Duyn
    Laboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA
    Nat Clin Pract Cardiovasc Med 5:S71-8. 2008
    ..At present, few MRI data characterizing the neural circuits in the heart are available, but in this Article we discuss the applicable present developments and the prospects for the future...
  88. ncbi TNFalpha in experimental diseases of the CNS
    Roberto Furlan
    Department of Neurology, San Raffaele Scientific Institute, Milan, Italy
    Methods Mol Med 98:171-90. 2004
    ..The application of innovative research strategies or original therapeutic approaches to these experimental models may be rewarding in terms of advancement in a field that is crucial for the management of many human patients...
  89. ncbi Chemokines and brain functions
    Ghazal Banisadr
    INSERM U 732 UPMC, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Curr Drug Targets Inflamm Allergy 4:387-99. 2005
    ....
  90. pmc Magnetic resonance imaging of the central nervous system in children with a new nonionic gadolinium contrast agent--gadoteridol injection (ProHance)
    S E Byrd
    Department of Radiology, Children s Memorial Hospital, Chicago, IL 60614
    J Natl Med Assoc 85:361-6. 1993
    ..Gadoteridol injection is a safe and excellent contrast agent for use in MRI...
  91. ncbi Neuroimaging of central nervous system infections
    J V Hunter
    Department of Radiology, Baylor College of Medicine, Texas Children s Hospital, Houston, TX 77030, USA
    Semin Pediatr Infect Dis 14:140-64. 2003
    ....
  92. ncbi Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome
    Ruth H Walker
    Departments of Neurology, Veterans Affairs Medical Center, New York, New York 10468, USA
    Mov Disord 22:244-8. 2007
    ..This phenotypic variation, despite shared mutations, suggests the action of disease-modifying factors that may explain some of the difficulties with genotype-phenotype correlation in McLeod syndrome...
  93. pmc From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases
    Monique Dubois-Dalcq
    National Institute of Neurological Disorders and Stroke, Porter Neuroscience Research Center, Bethesda, MD 20892 3706, USA
    Brain 131:1686-700. 2008
    ..We propose that expansion of this research field will help find ways to maintain or enhance spontaneous remyelination in man...
  94. ncbi TWEAK and the central nervous system
    Manuel Yepes
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, USA
    Mol Neurobiol 35:255-65. 2007
    ..In addition, inhibition of TWEAK activity by either treatment with a Fn14-Fc fusion protein or neutralizing anti-TWEAK antibodies has shown therapeutic efficacy in animal models of ischemic stroke, cerebral edema, and multiple sclerosis...
  95. ncbi Ill-defined neurological syndromes with autoimmune background: a diagnostic challenge
    Clio P Mavragani
    Department of Pathophysiology, National University of Athens, Greece
    J Rheumatol 34:341-5. 2007
    ..To define the diagnostic features of a cohort of patients presenting with autoimmune manifestations and atypical neurological features not fulfilling criteria for a well defined neurological or connective tissue disorder...
  96. ncbi First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability
    Yann Mikaeloff
    Service de Neurologie Pediatrique, Hopital Roger Salengro, Lille, France
    J Pediatr 144:246-52. 2004
    ..To evaluate prognostic factors for second attack and for disability in children presenting with an initial episode of central nervous system (CNS) demyelination...
  97. ncbi Is optic neuritis more benign than other first attacks in multiple sclerosis?
    Mar Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 57:210-5. 2005
    ..Optic neuritis has a smaller risk for conversion to multiple sclerosis. Nevertheless, MRI at baseline, not CIS topography, appears to be the crucial issue at multiple sclerosis presentation...
  98. ncbi An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions
    Sándor P Manninger
    Department of Radiology, Oregon Health and Science University, Portland, OR, USA
    AJNR Am J Neuroradiol 26:2290-300. 2005
    ....
  99. ncbi Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity
    Elisabeth J Rushing
    Department of Neuropathology and Ophthalmic Pathology, Armed Forces Institute of Pathology, Washington, District of Columbia 20306 6000, USA
    J Neuropathol Exp Neurol 67:819-27. 2008
    ..In this study, the degree of CD8+ inflammation was more pronounced in the single fatal example, and mast cells were not identified in the infiltrates. Although nonspecific, imaging findings may offer clues to early diagnosis...
  100. ncbi Trigeminal neuralgia in a patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
    Selcuk Peker
    Department of Neurosurgery, Marmara University, Marmara University Neurological Sciences Institute, Istanbul, Turkey
    J Clin Neurosci 12:172-4. 2005
    ..To our knowledge, this is the first case in the literature of MNGIE with trigeminal neuralgia. An analogy is suggested between multiple sclerosis and MNGIE as a cause for trigeminal neuralgia in this patient...
  101. ncbi Inflammatory and reparative tissue reaction in developing human central nervous system
    Maria Dambska
    Department of Experimental and Clinical Neuropathology, Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego St, 02 106 Warsaw, Poland
    Acta Neurobiol Exp (Wars) 64:475-80. 2004
    ..The topography of maturing brain lesions due to infections and anoxic/ischemic damage was similar and localized most often in the periventricular white matter...

Research Grants73

  1. Human embryonic stem cell-derived neural crest stem cells and Hirschsprung disea
    Sean J Morrison; Fiscal Year: 2010
    ..Transplantation/methods/*trends</keyword;keyword>Central Nervous System Diseases/*therapy</keyword;keyword>Cerebrovascular Accident/therapy</keyword;keyword>Clinical ..
  2. Dynamics of Kinesins, Dyneins, and Myosins
    Paul R Selvin; Fiscal Year: 2010
    ..as a function of insertion length of the cargo-binding domain of myosin VI (with L. Sweeney, UPenn.). d) Technological developments: Optics/microscopy needs to be achieved to fulfill the above goals. ..
  3. Brain Delivery of Nanoformulated Superoxide Dismutase
    Erin G Rosenbaugh; Fiscal Year: 2013
    ..In addition to the proposed scientific research, this fellowship will support the applicant's participation in nanotechnology-based coursework and career development. ..
  4. The Role of the Terminal Complement Pathway in ALS
    Scott R Barnum; Fiscal Year: 2013
    ..immune system, drives neuroinflammation along with other inflammatory mediators in most, if not all, central nervous system diseases and infections. There is growing evidence that complement contributes to neurodegeneration in ALS...
  5. Control of Drug Delivery to the CNS: Modulating P-glycoprotein Activity
    William A Banks; Fiscal Year: 2013
    ..abstract_text> ..
  6. Regulation of HIV-1 by Rad51 in CNS cells
    Kamel Khalili; Fiscal Year: 2013
    ..The identification of novel host-viral interaction pathways can provide important information regarding the pathogenesis of AIDS/CNS disease and promote the development of more effective therapeutic strategies. ..
  7. Air pollution and the brain: gender as an important determinant of susceptibility
    Lucio G Costa; Fiscal Year: 2013
    ....
  8. Analysis of alphaVbeta8 Integrin In Gliomagenesis
    Joseph H McCarty; Fiscal Year: 2012
    ..These results may identify new therapeutic targets to treat or prevent the development of gliomas in humans. ..
  9. HIV-CNS Diseases and Parasitic Zoonoses in the Eastern Cape, South Africa
    HELENE CARABIN; Fiscal Year: 2010
    ..Learning more about the parasitic infection/HIV interaction could better prevent neurological disease in people with HIV. ..
  10. Role of ABC efflux transporters in ALS
    Davide Trotti; Fiscal Year: 2013
    ..In this application we propose to study the regulation and role of these ABC transporters in ALS. Our ultimate goal is to understand the pathogenic mechanisms of ALS to improve the chances of success of pharmacotherapy for this disease. ..
  11. Innate immunity in Rett pathology and repair
    Jonathan Kipnis; Fiscal Year: 2013
    ....
  12. Small-molecule probes of chromatin-mediated neuroplasticity
    Stephen J Haggarty; Fiscal Year: 2013
    ..These multidisciplinary studies will shed new light on molecular mechanisms of brain plasticity and the relevance of these mechanisms to the development of novel therapeutics for their treatment of memory and mood disorders. ..
  13. Theiler?s virus as a potential cause of Vilyuisk encephalitis
    HOWARD LEE LIPTON; Fiscal Year: 2010
    ..The murine counterpart, Theiler's murine encephalomyelitis virus, provides a highly relevant experimental animal model for multiple sclerosis. ..
  14. Human Blood-Brain Barrier Model for CNS Drug Translation
    Eric V Shusta; Fiscal Year: 2010
    ..Finally, a detailed understanding of EGFR inhibitor permeability and efficacy using the human BBB model along with brain tumor isolates could have substantial impact on the translation of this class of medicines to the clinic. ..
  15. MR and BL Tracking of Stem/Progenitor Cells in the CNS
    Jeff W Bulte; Fiscal Year: 2013
    ..The ultimate goal is to develop ways of reporting on successful cell transplantation without removing any tissue, and to provide neurologists with a means to evaluate stem cell treatment in their patients. ..
  16. Treatment for Dysmyelination in PMD and SPG2
    Pamela E Knapp; Fiscal Year: 2013
    ..Further, the strategy of silencing developed here should be applicable to other diseases involving dominant, negative mutations. ..
  17. Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
    DANIEL MARTIN WATTERSON; Fiscal Year: 2013
    ..falls well within this timeline and offers the potential for new molecular entity (NME) entry into the multi-drug arsenal needed to delay onset, slow progression, and treat existing AD across the long timeline of disease progression ..
  18. Radiolabled MAO-B Substrates for Imaging
    Michael R Kilbourn; Fiscal Year: 2012
    ..The overall goal of the project is to identify appropriate radiolabeled substrates that can be further evaluated and validated for applications in human PET imaging. ..
  19. ALTERATIONS IN ADULT NEUROGENESIS DURING WEST NILE VIRUS ENCEPHALITIS
    MICHAEL JOHN VASEK; Fiscal Year: 2013
    ..Furthermore, knowledge about the behavior of neural stem cells within inflamed conditions may help guide the development of stem cell-based therapeutics for other CNS diseases with inflammation. ..
  20. Overcoming Membrane Transporters to Improve CNS Drug Therapy
    Robert S B Clark; Fiscal Year: 2013
    ....
  21. The role of VWF and platelets in BBB alterations associated with hypoxia
    GEORGETTE LEILA SUIDAN; Fiscal Year: 2013
    ....
  22. Identification of Biomarkers for BBB Injury-Induced by Drugs and HIV-1 Proteins
    Sheng He Huang; Fiscal Year: 2013
    ..2). Determine the correlation between disease-specific BBB injury and blood levels of biomarkers by molecular typing and single-cell profiling of cBMEC. ..
  23. Citicoline Treatment of Methamphetamine Dependence
    PERRY FRANKLIN RENSHAW; Fiscal Year: 2010
    ..The complementary measures of both neuropsychological function and multimodal neuroimaging following an 8-week citicoline trial will provide new insights and treatment strategies for this significant public health concern. ..
  24. Lipid electrophile adduction of Pin1 and effects on substrate binding &activity
    Christopher D Aluise; Fiscal Year: 2013
    ..Oxidative damage to cellular lipids is a contributing factor to aging, as well as many peripheral and central nervous system diseases. Reactive oxygen species-induced modification of polyunsaturated fatty acids results in the ..
  25. Nogo's role in intracellular trafficking
    Noam Y Harel; Fiscal Year: 2010
    ..targeting the Nogo-NgR pathway show promise in the treatment of spinal cord injury and other central nervous system diseases. However, much remains unknown regarding Nogo's function in uninjured cells...
  26. Clavulanic acid: a potential abuse-deterrent and CNS-active therapeutic
    Scott M Rawls; Fiscal Year: 2012
    ..Utilization of this proven strategy here may identify a novel CNS-active therapeutic, in much the same way that valproic acid is used to manage prostate cancer and NSAIDs are used to manage Alzheimer's disease. ..
  27. In Vivo Neuronal Modulation via Engineered G Protein-Coupled Receptors
    SARAH CLAIRE ROGAN; Fiscal Year: 2012
    ..manipulating neuronal GPCR signaling in vivo. Additionally, the particular signaling pathways this proposal will investigate could reveal critical information regarding the etiology and treatment of mental illness. ..
  28. A Robust, Automated, Flexible System for Mouse Behavioral Informatics
    BARTON GARRETT SELBY; Fiscal Year: 2011
    ..This proposal aims to develop a unique and powerful new technology for robust, automated, and comprehensive behavioral analysis of preclinical CNS disease models to facilitate discovery of new treatments for CNS diseases. ..
  29. Selection-driven plant metabolites for treatment of CNS diseases
    John M Littleton; Fiscal Year: 2011
    ..Its simplicity and rapidity suggests that it may compete with the existing synthetic chemistry approaches, and might even revitalize the use of plants as a source of medicines for CNS disease. ..
  30. In vitro tools for preclinical analysis of cognitive therapies for schizophrenia
    KRISTEN RICHARDSON; Fiscal Year: 2012
    ....
  31. Exploring the Role of the Brain Transcriptome in Cognitive Decline
    Philip L De Jager; Fiscal Year: 2013
    ..proven very effective in other human disorders have now begun to yield dividends in aging-related central nervous system diseases. The challenge is now turning to understanding the functional consequences within the brain of ..
  32. Brain-targeted nanomedicine via buccal administration
    Hu Yang; Fiscal Year: 2010
    ..This project will also explore buccal administration for systemic delivery of the proposed nanomedicine to reduce treatment cost and societal burden, increase patient compliance as well as improve the quality of the overall treatment. ..
  33. Gaucher disease:Treatment of neurodegenerative disease
    Dao Pan; Fiscal Year: 2013
    ..The approaches developed in the studies have general and significant applicability to neurodegenerative diseases including other LSDs, and Parkinson and Alzheimer diseases. ..
  34. Role of System xc- in Addiction: Developing &Phenotyping a Slc7a11 knockout rat
    Aron M Geurts; Fiscal Year: 2013
    ....
  35. Elucidation of M5 Muscarinic Receptor Neurophysiology using Allosteric Modulators
    Daniel J Foster; Fiscal Year: 2013
    ..These studies are important to both elucidate the physiological role of M5 as well as to validate the therapeutic potential of M5 modulation in multiple CNS diseases such as Parkinson's Disease, ADHD, and drug addiction. ..
  36. Localized immobilization of ephrin-B2 for neurite guidance in 3D culture
    Michael J Moore; Fiscal Year: 2010
    ..The use of functional biomaterials that are able to selectively guide growing axons may suggest new treatment strategies for optic nerve and other central nervous system disorders. ..
  37. CD200 as a monocyte/macrophage switch for brain repair after stroke
    Kazuhide Hayakawa; Fiscal Year: 2013
    ..I will learn the biomaterials and in vivo optical imaging tools from my mentor/consultants. My long term goal is to grow and build my independent lab based on the theme of manipulating inflammation for brain repair. ..
  38. DEVELOPMENT OF SYNAPTIC PATHWAYS IN RETINA
    Ning Tian; Fiscal Year: 2013
    ....
  39. Complement protection and anaphylatoxins in neuroinflammation
    Brian Martin; Fiscal Year: 2009
    ..This information will be critical for understanding how and when complement might be a candidate therapeutic target in CNS disease. ..
  40. Qualification of Novel Immune Markers in Human Serum of Patients with MS
    Michelle Sexton; Fiscal Year: 2010
    ..This F32 will provide support for the training of a new investigator involved in research which will help the public and health professional understand more about mechanisms of action of a CAM therapy. ..
  41. Role of Brain Estradiol in the Treatment of Male Depression and Anxiety
    Laszlo Prokai; Fiscal Year: 2013
    ....
  42. In Vivo Control and Functional Visualization of Stem Cell-Driven CNS Regeneration
    Jin Hyung Lee; Fiscal Year: 2010
    ..This project, upon its success, will provide direct and functional assessment capabilities for the regenerated nerve tissue in vivo. This in turn will provide key guidance for developing novel stem cell therapies for CNS diseases. ..
  43. Neuron Target Interaction - a Developmental Genetic Study
    Karl Herrup; Fiscal Year: 2010
    ....
  44. The role of chemoattractant receptors in central nervous system diseases
    Pablo Iribarren; Fiscal Year: 2012
    ....
  45. 2010 Myelin Gordon Research Conference
    Wendy B Macklin; Fiscal Year: 2010
    ..This highlights the potential clinical implications for our investigations on myelination and remyelination. ..
  46. Design of Class-specific HDAC Imaging Probes for Positron Emission Tomography
    Jacob M Hooker; Fiscal Year: 2013
    ..The outcome of this research will be a new technology for imaging epigenetic processes in vivo that can be used in both preclinical research and human studies. ..
  47. New Electroanalytical Methods for Single-Cell Exocytosis
    Bo Zhang; Fiscal Year: 2013
    ..As such, a detailed understanding of single exocytotic events is needed for better treatments for central nervous system diseases. Electroanalytical methods have played vital roles in this bioanalytical task in the past three ..
  48. Novel rhoptry effector proteins in Toxoplasma host-pathogen interaction
    PETER JOHN BRADLEY; Fiscal Year: 2013
    ..Together, these complementary approaches promise to reveal novel mechanistic insights into how Toxoplasma uses this unique set of effector proteins to modulate its mammalian host cell. ..
  49. Selection-driven plant metabolites for treatment of CNS diseases
    John M Littleton; Fiscal Year: 2013
    ..The ultimate aim is to commercialize the technology as a platform for discovering and producing novel plant-derived natural products targeted on specific human CNS proteins. ..
  50. 3D Structure of Membrane Proteins
    Michael Radermacher; Fiscal Year: 2013
    ..We will determine the 3D structure of Complex I in different catalytic states to obtain insights into the function of this highly complicated enzyme. 1 ..
  51. A Comprehensive Platform for Transporter Mediated Drug-Drug Interaction Studies
    Yong Huang; Fiscal Year: 2012
    ....
  52. In Vitro Dynamics of Kinesin 1 and Myosin VI
    Paul R Selvin; Fiscal Year: 2012
    ..Problems within the motors cause brain cancer, Alzheimer's disease, etc. We seek to understand the basic workings of kinesins and myosin VI, two important motors. ..
  53. T CELL RECOGNITION OF MYELIN IN MULTIPLE SCLEROSIS
    David A Hafler; Fiscal Year: 2010
    ....
  54. Development of small molecule Limk inhibitors for probing ocular diseases
    Philip LoGrasso; Fiscal Year: 2012
    ..These compounds will serve as useful molecular tools to study the biological functions of Limk, and to probe ocular diseases and other Limk related CNS diseases. ) ..
  55. iPS Cell-Derived Neurons Carrying an allelic series of CNTNAP2 structural mutatio
    MARIA contact KARAYIORGOU; Fiscal Year: 2010
    ..promise in generating induced pluripotent stem (iPS) cell lines from patients afflicted with central nervous system diseases, including psychiatric disorders...
  56. 2012 Myelin Gordon Research Conference &Gordon Research Seminar
    James Salzer; Fiscal Year: 2012
    ..In keeping with the goals of the Gordon Research Conference, such interactions will provide impetus and accelerate progress in the field of myelin biology. ..
  57. Post-translational Regulation of Opioid and Cannabinoid Receptors
    Lakshmi A Devi; Fiscal Year: 2013
    ....
  58. Novel PDE5 inhibitors as a therapeutic tool against Alzheimer's Disease
    Ottavio Arancio; Fiscal Year: 2013
    ..However, none of the existing inhibitors has been developed to counteract CNS diseases. We now propose to find phosphodiesterase 5 inhibitors that might be used in chronic CNS diseases such as Alzheimer's disease. ..
  59. Metabolomic Signatures and Biomarkers for Schizophrenia
    RIMA F KADDURAH-DAOUK; Fiscal Year: 2011
    ..If we succeed in discovering a disease signature for schizophrenia, this could provide an external validating measure that will improve clinical and may offer leads to the underlying pathophysiology of schizophrenia. ..
  60. 2010 Barriers of the CNS Gordon Research Conference
    Gert Fricker; Fiscal Year: 2010
    ....
  61. Confocal Microscope for the Study of Neurologic Diseases
    Tracy L Young-Pearse; Fiscal Year: 2012
    ....
  62. Heterologous expression of an invertebrate sodium channel for neuronal activation
    ADAM RORY MCQUISTON; Fiscal Year: 2010
    ..These studies will provide us with a model to understand the role of specific neurons in normal brain function and in psychiatric and neurological disorders. ..
  63. Functional Restoration of the Optic Nerve After Disease or Damage
    Dong Feng Chen; Fiscal Year: 2010
    ..The results of these proposed studies will open the door for future development of treatment strategies for optic nerve damage after disease or injury. ..
  64. Human Neurotropic JC Virus and CNS Diseases
    Kamel Khalili; Fiscal Year: 2006
    ..abstract_text> ..
  65. SUBSTANCE P, NO & MICROGLIA IN CNS INFLAMMATION
    Barnett Nathan; Fiscal Year: 2003
    ..SP and NO modulate their effects in CNS inflammation via these cells. Hypothesis 4: The ultimate site for the effects of SP and NO may be the mitochondrial respiratory chain enzymes of these phagocytic cells. ..
  66. A Nonisotopic HTS Assay to Elucidate Choline Transporter (CHT) Modulators
    ALICIA RUGGIERO; Fiscal Year: 2009
    ....
  67. CATECHOLAMINES, ANTIOXIDANTS AND OXIDATIVE STRESS
    Kandatege Wimalasena; Fiscal Year: 2003
    ..The degneration of catecholaminergic neurons in aging and central nervous system diseases such as Parkinson's Disease, as well as in the use of illicit drugs such as amphetamines have been ..
  68. COST-EFFECTIVE MANAGEMENT OF HIV-RELATED ILLNESSES
    Anna Tosteson; Fiscal Year: 1991
    ..Many HIV-related central nervous system diseases are potentially treatable, but rapidly fatal if undiagnosed...
  69. Force Plate Actometer for Measuring Behavior in Rodents
    Candice Kissinger; Fiscal Year: 2003
    ..abstract_text> ..
  70. NEW CNS DOPAMINE RECEPTOR IMAGING AGENTS
    HANK KUNG; Fiscal Year: 2002
    ....
  71. Improving the CNS Delivery of Anti-retroviral Compounds
    WILLIAM ELMQUIST; Fiscal Year: 2007
    ..New approaches to improve brain penetration of anti-HIV drugs will be valuable in the treatment of HIV-encephalopathy and in eradicating the virus from potential sanctuary sites. ..
  72. DRUG SELF ADMINISTRATION IN MOUSE MODELS OF NEUROAIDS
    Lisa Gold; Fiscal Year: 1999
    ....
  73. MOLEC PATHOPHYS OF CLIN VARIATION IN SPINAL CORD DISEASE
    Eric Hoffman; Fiscal Year: 2001
    ..Our findings should have significance for the progression of inherited forms of spastic paraplegia but also more broadly for spinal cord injury and CNS homeostasis. ..